Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroesophageal Cancer (GC)”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Testing effectiveness (Phase 2)Study completedNCT06238752
What this trial is testing

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC

Who this might be right for
Advanced Gastric Adenocarcinoma
Renmin Hospital of Wuhan University 33
Post-approval studies (Phase 4)Not Yet RecruitingNCT07502027
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Huazhong University of Science and Technology 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07045805
What this trial is testing

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Who this might be right for
Gastric Cancer (GC)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT03421288
What this trial is testing

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 677
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06238167
What this trial is testing

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

Who this might be right for
Gastric Cancer
First Affiliated Hospital of Wenzhou Medical University 40
Testing effectiveness (Phase 2)Looking for participantsNCT07315854
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer (GC)Gastroesophageal Junction CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital 32
Large-scale testing (Phase 3)Not Yet RecruitingNCT07362186
What this trial is testing

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LaNova Medicines Limited 400
Large-scale testing (Phase 3)Active Not RecruitingNCT04592913
What this trial is testing

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Who this might be right for
Gastrointestinal NeoplasmsEsophagogastric Junction
AstraZeneca 957
Testing effectiveness (Phase 2)Active Not RecruitingNCT04817826
What this trial is testing

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

Who this might be right for
Gastric CancerMicrosatellite Instability
Gruppo Oncologico del Nord-Ovest 31
Testing effectiveness (Phase 2)WithdrawnNCT03704077
What this trial is testing

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerCancer of the StomachStomach Cancer+1 more
Bristol-Myers Squibb
Large-scale testing (Phase 3)Not Yet RecruitingNCT07518147
What this trial is testing

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 438
Testing effectiveness (Phase 2)Looking for participantsNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 172
Large-scale testing (Phase 3)Study completedNCT03813784
What this trial is testing

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Who this might be right for
Gastric CancerGastroEsophageal Cancer
Jiangsu HengRui Medicine Co., Ltd. 885
Early research (Phase 1)Looking for participantsNCT07419841
What this trial is testing

The Safety and Tolerability of CTX-10726

Who this might be right for
Gastroesophageal Cancer (GC)Hepatocellular Carcinoma (HCC)Endometrial Cancer+1 more
Compass Therapeutics 70
Not applicableActive Not RecruitingNCT04891900
What this trial is testing

TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerAdenocarcinoma of Esophagogastric Junction
Henan Cancer Hospital 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06222944
What this trial is testing

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Who this might be right for
Gastric CancerAdenocarcinoma of Esophagogastric Junction
Peking University 90
Early research (Phase 1)Looking for participantsNCT06773312
What this trial is testing

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Advanced or Metastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. 80
Testing effectiveness (Phase 2)Looking for participantsNCT06023758
What this trial is testing

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Who this might be right for
HER2-positive Locally Advanced Resectable Gastric Cancer
Peking University 18
Testing effectiveness (Phase 2)Looking for participantsNCT06572319
What this trial is testing

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Zhejiang Cancer Hospital 35
Testing effectiveness (Phase 2)Looking for participantsNCT06742411
What this trial is testing

XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC

Who this might be right for
Gastric (Stomach) Cancer
West China Hospital 57
Load More Results